Ana M. Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ana M. Cruz has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Britt Otten
Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK
2 shared publications- Craig Beall
University of Exeter
2 shared publications - Julia M. Vlachaki Walker
Faculty of Medicine London England Imperial College London Institute of Clinical Sciences
2 shared publications - Kate L. J. Ellacott
Department of Clinical and Biomedical Sciences University of Exeter Medical School Exeter UK
2 shared publications Mandy V Dunlop
Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK
2 shared publications- Marlou L. Dirks
Nutritional Physiology Research Group, Department of Public Health and Sport Sciences, Faculty of Health and Life Sciences, University of Exeter , Exeter, Devon EX1 2LU
2 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 20
Inhibition of Low-Density Lipoprotein Oxidation by Cysteamine, Cystamine, Cysteine and Cystine at Lysosomal pH and pH 7.4
LDL can be oxidised in the lysosomes of macrophages. Cysteamine, a thiol antioxidant that accumulates in lysosomes, inhibits the oxidation of LDL by iron at lysosomal pH (pH 4.5) and protects against atherosclerosis in mice. We have investigated the effects of cysteamine and its related thiol cysteine and their disulfides on LDL oxidation by iron or copper at both pH 4.5 and 7.4. The oxidation of LDL by ferrous iron (5 µM) at pH 4.5 was delayed 12.9-fold by 100 µM cysteamine and 5.6-fold by 100 µM cysteine. Cystamine and cystine (the disulfide oxidation products of cyteamine and cysteine, respectively) did not inhibit LDL oxidation by ferrous iron at pH 4.5. LDL oxidation by 5 µM copper at pH 4.5 was delayed about 2-fold by 100 µM of the thiols cysteamine and cysteine, but there was little effect of the disulfides cystamine and cystine. Cysteamine and cystine did not inhibit the oxidation of LDL by ferrous iron at pH 7.4 in a MOPS buffer and even accelerated LDL oxidation later in the incubation. Cysteine initially inhibited the oxidation of LDL by ferrous iron at pH 7.4, but increased it later. LDL oxidation by copper at pH 7.4 was delayed 7.8-fold by 100 µM cysteamine. Cysteine delayed LDL oxidation by copper at pH 7.4 to a similar extent as cysteamine but, unlike cysteamine, continued to decrease the rate of oxidation even after the period of total inhibition had ended. Cystamine had no effect on LDL oxidation by copper at pH 7.4, but cystine partially inhibited LDL oxidation. The effects of thiols and disulfides on LDL oxidation, therefore, depend not only on the metal ion catalysing the oxidation but also on the pH of the environment.
- 22 December 2025
- Published by MDPI AG in Antioxidants
- Vol. 15 (1) , 20
Open AccessInhibition of Low-Density Lipoprotein Oxidation by Cysteamine, Cystamine, Cysteine and Cystine at Lysosomal pH and pH 7.4
LDL can be oxidised in the lysosomes of macrophages. Cysteamine, a thiol antioxidant that accumulates in lysosomes, inhibits the oxidation of LDL by iron at lysosomal pH (pH 4.5) and protects against atherosclerosis in mice. We have investigated the effects of cysteamine and its related thiol cysteine and their disulfides on LDL oxidation by iron or copper at both pH 4.5 and 7.4. The oxidation of LDL by ferrous iron (5 µM) at pH 4.5 was delayed 12.9-fold by 100 µM cysteamine and 5.6-fold by 100 µM cysteine. Cystamine and cystine (the disulfide oxidation products of cyteamine and cysteine, respectively) did not inhibit LDL oxidation by ferrous iron at pH 4.5. LDL oxidation by 5 µM copper at pH 4.5 was delayed about 2-fold by 100 µM of the thiols cysteamine and cysteine, but there was little effect of the disulfides cystamine and cystine. Cysteamine and cystine did not inhibit the oxidation of LDL by ferrous iron at pH 7.4 in a MOPS buffer and even accelerated LDL oxidation later in the incubation. Cysteine initially inhibited the oxidation of LDL by ferrous iron at pH 7.4, but increased it later. LDL oxidation by copper at pH 7.4 was delayed 7.8-fold by 100 µM cysteamine. Cysteine delayed LDL oxidation by copper at pH 7.4 to a similar extent as cysteamine but, unlike cysteamine, continued to decrease the rate of oxidation even after the period of total inhibition had ended. Cystamine had no effect on LDL oxidation by copper at pH 7.4, but cystine partially inhibited LDL oxidation. The effects of thiols and disulfides on LDL oxidation, therefore, depend not only on the metal ion catalysing the oxidation but also on the pH of the environment.
- Open Access
- 18 April 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , e2547-e2562
The Impact of Disuse and High-Fat Overfeeding on Forearm Muscle Amino Acid Metabolism in Humans
Context Anabolic resistance is mechanistically implicated in muscle disuse atrophy. Objective Assess whether anabolic resistance is associated with reduced postprandial amino acid uptake or exacerbated by excess lipid availability. Design, setting, participants and interventions Twenty men underwent 7 days of forearm immobilization while consuming a eucaloric (CON; n=11) or high-fat overfeeding (HFD; n=9; 50% excess energy as fat) diet (parallel design) within our Nutritional Physiology Research Unit. Main outcome measures Pre- and post- immobilization we measured forearm muscle cross sectional area (aCSA), and postabsorptive and postprandial (3 h post ingestion of a liquid, protein rich, mixed meal) forearm amino acid metabolism using the arterialised venous-deep venous balance method and infusions of L-[ring-2H5]phenylalanine and L-[1-13C]leucine. Results Immobilization did not affect forearm muscle aCSA in either group, but tended to reduce postabsorptive phenylalanine (P=0.07) and leucine (P=0.05) net balances equivalently in CON and HFD. Mixed meal ingestion switched phenylalanine and leucine net balances from negative to positive (PPPd; P0.05). Conclusions Disuse impairs the ability of a protein-rich meal to promote positive muscle amino acid balance, which is aggravated by dietary lipid oversupply. Moreover, disuse reduced postprandial forearm amino acid uptake; however, this is not worsened under high-fat conditions.
- 18 April 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , e2547-e2562
Open AccessThe Impact of Disuse and High-Fat Overfeeding on Forearm Muscle Amino Acid Metabolism in Humans
Context Anabolic resistance is mechanistically implicated in muscle disuse atrophy. Objective Assess whether anabolic resistance is associated with reduced postprandial amino acid uptake or exacerbated by excess lipid availability. Design, setting, participants and interventions Twenty men underwent 7 days of forearm immobilization while consuming a eucaloric (CON; n=11) or high-fat overfeeding (HFD; n=9; 50% excess energy as fat) diet (parallel design) within our Nutritional Physiology Research Unit. Main outcome measures Pre- and post- immobilization we measured forearm muscle cross sectional area (aCSA), and postabsorptive and postprandial (3 h post ingestion of a liquid, protein rich, mixed meal) forearm amino acid metabolism using the arterialised venous-deep venous balance method and infusions of L-[ring-2H5]phenylalanine and L-[1-13C]leucine. Results Immobilization did not affect forearm muscle aCSA in either group, but tended to reduce postabsorptive phenylalanine (P=0.07) and leucine (P=0.05) net balances equivalently in CON and HFD. Mixed meal ingestion switched phenylalanine and leucine net balances from negative to positive (PPPd; P0.05). Conclusions Disuse impairs the ability of a protein-rich meal to promote positive muscle amino acid balance, which is aggravated by dietary lipid oversupply. Moreover, disuse reduced postprandial forearm amino acid uptake; however, this is not worsened under high-fat conditions.
- 14 October 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (1) , 276-289
High-fat Overfeeding Does Not Exacerbate Rapid Changes in Forearm Glucose and Fatty Acid Balance During Immobilization
Context Physical inactivity and high-fat overfeeding have been shown to independently induce insulin resistance. Objective Establish the contribution of muscle disuse and lipid availability to the development of inactivity-induced insulin resistance. Design, setting, participants, and interventions: Twenty healthy males underwent seven days of forearm cast immobilization combined with a fully-controlled eucaloric (CON, n=10, age 23±2 yr, BMI 23.8±1.0 kg·m-2) or high-fat diet providing 50% excess energy from fat (HFD, n=10, age 23±2 yr, BMI 22.4±0.8 kg·m-2). Main outcome measures Prior to casting, and following 2 and 7 days of immobilization, forearm glucose uptake (FGU) and non-esterified fatty acid (NEFA) balance were assessed using the arterialized venous-deep venous (AV-V) forearm balance method following ingestion of a mixed macronutrient drink. Results Seven days of HFD increased body weight by 0.9±0.2 kg (P=0.002), but did not alter fasting, arterialized whole-blood glucose and serum insulin concentrations or the associated HOMA-IR or Matsuda indices. Two and seven days of forearm immobilization led to a 40±7% and 52±7% decrease in FGU, respectively (PP=0.095). Conclusions forearm immobilization leads to a rapid and substantial decrease in FGU, which is accompanied by an increase in forearm NEFA balance but is not exacerbated by excess dietary fat intake. Altogether, our data suggest that disuse-induced insulin resistance of glucose metabolism is occurs as a physiological adaptation in response to the removal of muscle contraction.
- 14 October 2019
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (1) , 276-289
High-fat Overfeeding Does Not Exacerbate Rapid Changes in Forearm Glucose and Fatty Acid Balance During Immobilization
Context Physical inactivity and high-fat overfeeding have been shown to independently induce insulin resistance. Objective Establish the contribution of muscle disuse and lipid availability to the development of inactivity-induced insulin resistance. Design, setting, participants, and interventions: Twenty healthy males underwent seven days of forearm cast immobilization combined with a fully-controlled eucaloric (CON, n=10, age 23±2 yr, BMI 23.8±1.0 kg·m-2) or high-fat diet providing 50% excess energy from fat (HFD, n=10, age 23±2 yr, BMI 22.4±0.8 kg·m-2). Main outcome measures Prior to casting, and following 2 and 7 days of immobilization, forearm glucose uptake (FGU) and non-esterified fatty acid (NEFA) balance were assessed using the arterialized venous-deep venous (AV-V) forearm balance method following ingestion of a mixed macronutrient drink. Results Seven days of HFD increased body weight by 0.9±0.2 kg (P=0.002), but did not alter fasting, arterialized whole-blood glucose and serum insulin concentrations or the associated HOMA-IR or Matsuda indices. Two and seven days of forearm immobilization led to a 40±7% and 52±7% decrease in FGU, respectively (PP=0.095). Conclusions forearm immobilization leads to a rapid and substantial decrease in FGU, which is accompanied by an increase in forearm NEFA balance but is not exacerbated by excess dietary fat intake. Altogether, our data suggest that disuse-induced insulin resistance of glucose metabolism is occurs as a physiological adaptation in response to the removal of muscle contraction.
- Open Access
Brain permeable AMPK activator R481 raises glycemia by autonomic nervous system activation and amplifies the counterregulatory response to hypoglycemia in rats
AMP-activated protein kinase (AMPK) is a critical cellular and whole body energy sensor activated by energy stress, including hypoglycemia, which is frequently experienced by people with diabetes. Previous studies using direct delivery of an AMPK activator to the ventromedial hypothalamus (VMH) in rodents increased hepatic glucose production. Moreover, recurrent glucoprivation in the hypothalamus leads to blunted AMPK activation and defective hormonal responses to subsequent hypoglycemia. These data suggest that amplifying AMPK activation may prevent or reduce frequency hypoglycemia in diabetes. We used a novel brain-permeable AMPK activator, R481, which potently increased AMPK phosphorylation in vitro . R481 significantly increased peak glucose levels during glucose tolerance tests in rats, which were attenuated by treatment with AMPK inhibitor SBI-0206965 and completely abolished by blockade of the autonomic nervous system. This occurred without altering insulin sensitivity measured by hyperinsulinemic-euglycemic clamps. Endogenous insulin secretion was not altered by R481 treatment. During hyperinsulinemic-hypoglycemic clamp studies, R481 treatment reduced exogenous glucose requirements and amplified peak glucagon levels during hypoglycemia. These data demonstrate that peripheral administration of the brain permeable AMPK activator R481 amplifies the counterregulatory response to hypoglycemia in rats, which could have clinical relevance for prevention of hypoglycemia.
Open AccessBrain permeable AMPK activator R481 raises glycemia by autonomic nervous system activation and amplifies the counterregulatory response to hypoglycemia in rats
AMP-activated protein kinase (AMPK) is a critical cellular and whole body energy sensor activated by energy stress, including hypoglycemia, which is frequently experienced by people with diabetes. Previous studies using direct delivery of an AMPK activator to the ventromedial hypothalamus (VMH) in rodents increased hepatic glucose production. Moreover, recurrent glucoprivation in the hypothalamus leads to blunted AMPK activation and defective hormonal responses to subsequent hypoglycemia. These data suggest that amplifying AMPK activation may prevent or reduce frequency hypoglycemia in diabetes. We used a novel brain-permeable AMPK activator, R481, which potently increased AMPK phosphorylation in vitro . R481 significantly increased peak glucose levels during glucose tolerance tests in rats, which were attenuated by treatment with AMPK inhibitor SBI-0206965 and completely abolished by blockade of the autonomic nervous system. This occurred without altering insulin sensitivity measured by hyperinsulinemic-euglycemic clamps. Endogenous insulin secretion was not altered by R481 treatment. During hyperinsulinemic-hypoglycemic clamp studies, R481 treatment reduced exogenous glucose requirements and amplified peak glucagon levels during hypoglycemia. These data demonstrate that peripheral administration of the brain permeable AMPK activator R481 amplifies the counterregulatory response to hypoglycemia in rats, which could have clinical relevance for prevention of hypoglycemia.
- Open Access
- 17 February 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (7) , 997-1005
AMP ‐activated protein kinase ( AMPK ) activator A ‐769662 increases intracellular calcium and ATP release from astrocytes in an AMPK ‐independent manner
Aim: To test the hypothesis that, given the role of AMP ‐activated protein kinase ( AMPK ) in regulating intracellular ATP levels, AMPK may alter ATP release from astrocytes, the main sources of extracellular ATP ( eATP ) within the brain. Materials and Methods: Measurements of ATP release were made from human U373 astrocytoma cells, primary mouse hypothalamic ( HTAS ) and cortical astrocytes ( CRTAS ) and wild‐type and AMPK α1/α2 null mouse embryonic fibroblasts ( MEFs ). Cells were treated with drugs known to modulate AMPK activity: A ‐769662, AICAR and metformin, for up to 3 hours. Intracellular calcium was measured using F luo4 and F ura‐2 calcium‐sensitive fluorescent dyes. Results: In U373 cells, A ‐769662 (100 μM) increased AMPK phosphorylation, whereas AICAR and metformin (1 mM) induced a modest increase or had no effect, respectively. Only A ‐769662 increased eATP levels, and this was partially blocked by AMPK inhibitor C ompound C . A‐769662‐induced increases in eATP were preserved in AMPK α1/α2 null MEF cells. A‐769662 increased intracellular calcium in U373 , HTAS and CRTAS cells and chelation of intracellular calcium using BAPTA‐AM reduced A ‐769662‐induced eATP levels. A‐769662 also increased ATP release from a number of other central and peripheral endocrine cell types. Conclusions: AMPK is required to maintain basal eATP levels but is not required for A ‐769662‐induced increases in eATP . A‐769662 (>50 μM) enhanced intracellular calcium levels leading to ATP release in an AMPK and purinergic receptor independent pathway.
- 17 February 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (7) , 997-1005
Open AccessAMP ‐activated protein kinase ( AMPK ) activator A ‐769662 increases intracellular calcium and ATP release from astrocytes in an AMPK ‐independent manner
Aim: To test the hypothesis that, given the role of AMP ‐activated protein kinase ( AMPK ) in regulating intracellular ATP levels, AMPK may alter ATP release from astrocytes, the main sources of extracellular ATP ( eATP ) within the brain. Materials and Methods: Measurements of ATP release were made from human U373 astrocytoma cells, primary mouse hypothalamic ( HTAS ) and cortical astrocytes ( CRTAS ) and wild‐type and AMPK α1/α2 null mouse embryonic fibroblasts ( MEFs ). Cells were treated with drugs known to modulate AMPK activity: A ‐769662, AICAR and metformin, for up to 3 hours. Intracellular calcium was measured using F luo4 and F ura‐2 calcium‐sensitive fluorescent dyes. Results: In U373 cells, A ‐769662 (100 μM) increased AMPK phosphorylation, whereas AICAR and metformin (1 mM) induced a modest increase or had no effect, respectively. Only A ‐769662 increased eATP levels, and this was partially blocked by AMPK inhibitor C ompound C . A‐769662‐induced increases in eATP were preserved in AMPK α1/α2 null MEF cells. A‐769662 increased intracellular calcium in U373 , HTAS and CRTAS cells and chelation of intracellular calcium using BAPTA‐AM reduced A ‐769662‐induced eATP levels. A‐769662 also increased ATP release from a number of other central and peripheral endocrine cell types. Conclusions: AMPK is required to maintain basal eATP levels but is not required for A ‐769662‐induced increases in eATP . A‐769662 (>50 μM) enhanced intracellular calcium levels leading to ATP release in an AMPK and purinergic receptor independent pathway.